Bend Research, part of Capsugel’s Dosage Form Solutions (DFS) business unit, is investing more than $20 million to expand commercial manufacturing for spray-dried dispersions at its facilities in Bend, OR. The company is adding two new high-capacity PSD spray dryer process trains capable of handling high-risk/high-potency compounds. The commercial facility expansion, along with the existing GMP development and manufacturing facility, will be completed and validated by mid-2015.
 
In addition to the new commercial production lines, the company is building a high-capacity PSD spray dryer in its process-development pilot facility for Scale-Up , quality-by-design studies ( QbD ), and the production of appropriate toxicology study supplies. The development spray dryer addition will be completed and operational in the spring of 2014.
 
“This major investment, after our acquisition of Bend Research, confirms our commitment to continue to expand the capabilities across our entire DFS organization,” said Guido Driesen, president and chief executive officer of Capsugel. “Our goal is to provide clients with innovative dosage form solutions by bringing together industry-leading R&D expertise and world-class manufacturing capabilities.”